February 25th 2020
Urologists must differentiate between bladder outlet obstruction and pure OAB in male patients, according to Osvaldo F. Padron, MD.
November 20th 2018
For BPH, bipolar, monopolar transurethral resection of the prostate show similar clinical efficacy
August 9th 2013In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
Reduced OR, laser time observed with newer PVP system
May 24th 2013The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.
AUA 2013: Newer OAB agent viable alternative to antimuscarinics
May 7th 2013Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.
AUA 2013: ‘Lift’ procedure shows durable improvement in LUTS
May 7th 2013Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.
AUA 2013: Men with LUTS more likely to have suicidal thoughts
May 7th 2013Building on previous research suggesting a cause-and-effect link between mental illness and urinary dysfunction, a new study finds that older men with two or more lower urinary tract symptoms are more likely to have recently had thoughts of suicide.
Newer overactive bladder agent viable alternative to antimuscarinics
April 23rd 2013Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.
Evolving algorithm for treating male voiding symptoms
April 18th 2013The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
Study questions botulinum’s efficacy in post-BPH overactive bladder
December 31st 2012Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.